Search research articles
Contact Us
Filters
Showing results (311-320 of 336) with videos related to
Page
of 34
Sort By:
European Urology
|
November 12, 2025
Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 Study
Ronan Flippot, Yann-Alexandre Vano, Cécile Dalban, et al.
BMC Cancer
|
February 11, 2025
The PENDOR study: establishment of a panel of patient-derived tumor organoids from endometrial cancer to assess efficacy of PARP inhibitors
Gwenn Le Gall, François Cherifi, Jordane Divoux, et al.
Journal of the National Cancer Institute
|
September 9, 2024
Long-term behavioral symptom clusters among survivors of early-stage breast cancer: Development and validation of a predictive model
Martina Pagliuca, Julie Havas, Emilie Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2022
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial
Jacobus Pfisterer, Florence Joly, Gunnar Kristensen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 8, 2026
ESR1 mutation in Endocrine treatment naive Endometrial Cancer: Prevalence, Characteristics and Prognostic Implications, results from the UTOLA phase II GINECO trial
Félix Blanc-Durand, Catherine Genestie, Sergey Nikolaev, et al.
Lancet (London, England)
|
December 4, 2023
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
Ana Oaknin, Laurence Gladieff, Jerónimo Martínez-García, et al.
Clinical Genitourinary Cancer
|
October 4, 2021
Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial
Stéphane Culine, Valentin Harter, Gwenaelle Gravis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 1, 2015
PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients
Anne de la Rochefordiere, Maud Kamal, Anne Floquet, et al.
The Lancet. Oncology
|
November 16, 2024
Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial
Jean-Marc Classe, Pierre Meeus, Delphine Hudry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 29, 2023
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial
Jean-Emmanuel Kurtz, Eric Pujade-Lauraine, Ana Oaknin, et al.
Page
of 34
Search research articles
Search
Showing results (311-320 of 336) with videos related to
Sort By:
Page
of 34
European Urology
|
November 12, 2025
Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 Study
Ronan Flippot, Yann-Alexandre Vano, Cécile Dalban, et al.
BMC Cancer
|
February 11, 2025
The PENDOR study: establishment of a panel of patient-derived tumor organoids from endometrial cancer to assess efficacy of PARP inhibitors
Gwenn Le Gall, François Cherifi, Jordane Divoux, et al.
Journal of the National Cancer Institute
|
September 9, 2024
Long-term behavioral symptom clusters among survivors of early-stage breast cancer: Development and validation of a predictive model
Martina Pagliuca, Julie Havas, Emilie Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2022
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial
Jacobus Pfisterer, Florence Joly, Gunnar Kristensen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 8, 2026
ESR1 mutation in Endocrine treatment naive Endometrial Cancer: Prevalence, Characteristics and Prognostic Implications, results from the UTOLA phase II GINECO trial
Félix Blanc-Durand, Catherine Genestie, Sergey Nikolaev, et al.
Lancet (London, England)
|
December 4, 2023
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
Ana Oaknin, Laurence Gladieff, Jerónimo Martínez-García, et al.
Clinical Genitourinary Cancer
|
October 4, 2021
Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial
Stéphane Culine, Valentin Harter, Gwenaelle Gravis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 1, 2015
PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients
Anne de la Rochefordiere, Maud Kamal, Anne Floquet, et al.
The Lancet. Oncology
|
November 16, 2024
Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial
Jean-Marc Classe, Pierre Meeus, Delphine Hudry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 29, 2023
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial
Jean-Emmanuel Kurtz, Eric Pujade-Lauraine, Ana Oaknin, et al.
Page
of 34